Neoadjuvant immune-checkpoint blockade therapy in combination with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING).
Neoadjuvant immune-checkpoint blockade therapy in combination with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING).
Shunli Shen, Shi‐Ting Feng, Li Tan, Wenxuan Xie et al.
Journal
Journal of Clinical Oncology
Topics
Hepatocellular Carcinoma Treatment and Prognosis
article
Neoadjuvant immune-checkpoint blockade therapy in combination with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING).
Brigham and Women's Hospital (US), Sun Yat-sen University (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Sun Yat-sen University Cancer Center (CN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Neoadjuvant immune-checkpoint blockade therapy in combination with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING). — Shunli Shen, Shi‐Ting Feng, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS